In this study, we have shown the feasibility of siRNA-mediated STAT5A silencing in ALL cell lines SUP-B15 and RS4;11 as well as ALL patient cells from different donors, using 2 lipid modified PEIs. The gene discussed is STAT5A; the disease is acute lymphoblastic leukemia.